Supplement evidence

083 / 575Digestive support

Alpha-galactosidase

View my plan →

The short answer

Helps digest gas-producing oligosaccharides in beans and selected foods, reducing post-meal gas in some people.

Evidence and scope: Supported for specific outcomes
This status does not grade the ingredient for every goal, outcome, or person.
Important limitation: Evidence supports a specific outcome, not a general wellness or longevity effect.
Before deciding: Key concern: Diabetes requires label review because digestion can increase absorbed carbohydrate; not for alpha-gal allergy.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective

Meal-specific digestionFollow product activity units with the first bites of the trigger meal

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityFat/water classification is not the key factor

Fat/water solubility is not the useful decision point; preparation, fluid, timing, or strain identity matters more.

How it is commonly taken

Take with the first bite of beans or other high-galactooligosaccharide food.

Do not combine casually

Diabetes requires label review because digestion can increase absorbed carbohydrate; not for alpha-gal allergy.

Dose and use source ↗

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

3research papers in this ledger

3unique primary studies represented

197unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

2021

Does not support the tested claimPMID 33619835

Acute alpha-galactosidase after high-oligosaccharide meals in IBS

Symptoms and breath gases did not differ from placebo. The small acute pilot directly argues against assuming that a gas-reduction mechanism reliably improves IBS symptoms.

Published: 2021Duration: Two standardized meal-test daysn=20 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled crossover pilot
Population: 20 adults with IBS, 19 women
Intervention: Alpha-galactosidase 1,200 GaIU per meal versus placebo with three high-oligosaccharide meals
Outcome: Gastrointestinal symptoms and breath hydrogen and methane over 7.5 hours

Open research record ↗

2016

Does not support the tested claimPMID 26133538

Does oral alpha-galactosidase relieve irritable bowel symptoms?

The trial found no evidence supporting routine IBS use and no quality-of-life difference. More participants withdrew with alpha-galactosidase, often citing pain or diarrhea, making a later responder signal vulnerable to dropout bias.

Published: 2016Duration: 12 weeks plus 4-week follow-upn=125 participants

Study design and methods

Design: Randomized placebo-controlled trial
Population: 125 adults with IBS and bloating or flatulence
Intervention: Oral alpha-galactosidase or placebo with meals
Outcome: IBS symptom severity, quality of life, withdrawal, and gastrointestinal adverse effects

Open research record ↗

2013

Mixed or qualifiedPMID 24063420 · NCT01595932

Alpha-galactosidase for gas-related symptoms in children

Global distress, days with moderate-to-severe bloating, and flatulence improved, while spasms and distension did not. No adverse events were reported, but the small short pediatric trial needs replication.

Published: 2013Duration: 2 weeksn=52 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled trial
Population: 52 children aged 4–17 with chronic or recurrent gas-related symptoms
Intervention: Weight-adjusted alpha-galactosidase drops or tablets versus placebo
Outcome: Global distress, bloating, flatulence, spasms, distension, and adverse events

Open research record ↗

Unscreened discovery appendix—not evidence7 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

Official evidence overviewPubMed bounded human-evidence search Live PubMed discovery searchNational Library of Medicine

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.